150 related articles for article (PubMed ID: 24570340)
41. The role of high density lipoprotein in Type 1 Gaucher disease.
Watad S; Abu-Saleh N; Yousif A; Agbaria A; Rosenbaum H
Blood Cells Mol Dis; 2018 Feb; 68():43-46. PubMed ID: 27876360
[TBL] [Abstract][Full Text] [Related]
42. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
Heitner R; Arndt S; Levin JB
S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
[TBL] [Abstract][Full Text] [Related]
43. Long-term bone mineral density response to enzyme replacement therapy in a retrospective pediatric cohort of Gaucher patients.
Ciana G; Deroma L; Franzil AM; Dardis A; Bembi B
J Inherit Metab Dis; 2012 Nov; 35(6):1101-6. PubMed ID: 22441841
[TBL] [Abstract][Full Text] [Related]
44. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.
Elstein D; Mellgard B; Dinh Q; Lan L; Qiu Y; Cozma C; Eichler S; Böttcher T; Zimran A
Mol Genet Metab; 2017 Sep; 122(1-2):113-120. PubMed ID: 28851512
[TBL] [Abstract][Full Text] [Related]
45. Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.
Grigorescu-Sido P; Drugan C; Alkhzouz C; Zimmermann A; Coldea C; Denes C; Grigorescu MD; Cret V; Bucerzan S
Eur J Intern Med; 2010 Apr; 21(2):104-13. PubMed ID: 20206881
[TBL] [Abstract][Full Text] [Related]
46. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
Kishnani PS; DiRocco M; Kaplan P; Mehta A; Pastores GM; Smith SE; Puga AC; Lemay RM; Weinreb NJ
Mol Genet Metab; 2009 Apr; 96(4):164-70. PubMed ID: 19195916
[TBL] [Abstract][Full Text] [Related]
47. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
Canda E; Kose M; Kagnici M; Ucar SK; Sozmen EY; Coker M
Blood Cells Mol Dis; 2018 Feb; 68():180-184. PubMed ID: 28111116
[No Abstract] [Full Text] [Related]
48. Enzyme replacement therapy for Gaucher Disease: the only experience in Malaysia.
Chan LL; Lin HP
Med J Malaysia; 2002 Sep; 57(3):348-52. PubMed ID: 12440275
[TBL] [Abstract][Full Text] [Related]
49. Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease.
Hsu CC; Chien YH; Lai MY; Hwu WL
J Formos Med Assoc; 2002 Sep; 101(9):627-31. PubMed ID: 12645190
[TBL] [Abstract][Full Text] [Related]
50. Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply.
Zimran A; Altarescu G; Elstein D
Blood Cells Mol Dis; 2011 Jan; 46(1):111-4. PubMed ID: 20542712
[TBL] [Abstract][Full Text] [Related]
51. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.
Pastores GM; Shankar SP; Petakov M; Giraldo P; Rosenbaum H; Amato DJ; Szer J; Chertkoff R; Brill-Almon E; Zimran A
Am J Hematol; 2016 Jul; 91(7):661-5. PubMed ID: 27102949
[TBL] [Abstract][Full Text] [Related]
52. Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.
Cravo R; Rotman V; Oliveira PMN; Defendi HGT; Conceição DA; Xavier JR; Chertkoff R; Noronha TG; Maia MLS
Blood Cells Mol Dis; 2018 Feb; 68():160-162. PubMed ID: 28131618
[TBL] [Abstract][Full Text] [Related]
53. Bone events and evolution of biologic markers in Gaucher disease before and during treatment.
Stirnemann J; Belmatoug N; Vincent C; Fain O; Fantin B; Mentré F
Arthritis Res Ther; 2010; 12(4):R156. PubMed ID: 20696071
[TBL] [Abstract][Full Text] [Related]
54. Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations.
Dinur T; Grittner U; Revel-Vilk S; Becker-Cohen M; Istaiti M; Cozma C; Rolfs A; Zimran A
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299318
[TBL] [Abstract][Full Text] [Related]
55. Assessment of the nlmixr R package for population pharmacokinetic modeling: A metformin case study.
Mak WY; Ooi QX; Cruz CV; Looi I; Yuen KH; Standing JF
Br J Clin Pharmacol; 2023 Jan; 89(1):330-339. PubMed ID: 35976674
[TBL] [Abstract][Full Text] [Related]
56. Velaglucerase alfa: a new option for Gaucher disease treatment.
Zimran A
Drugs Today (Barc); 2011 Jul; 47(7):515-29. PubMed ID: 22013559
[TBL] [Abstract][Full Text] [Related]
57. Outcome of enzyme replacement therapy in Turkish patients with Gaucher disease: does late intervention affect the response?
Arikan-Ayyildiz Z; Yüce A; Emre S; Baysoy G; Saltik-Temizel IN; Gürakan F
Turk J Pediatr; 2011; 53(5):499-507. PubMed ID: 22272449
[TBL] [Abstract][Full Text] [Related]
58. Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease.
Pastores GM
BioDrugs; 2010 Feb; 24(1):41-7. PubMed ID: 20055531
[TBL] [Abstract][Full Text] [Related]
59. [Safety of use of velaglucerase in 2 patients with type 1 Gaucher's disease].
Latre P; Giraldo P
Med Clin (Barc); 2011 Sep; 137 Suppl 1():39-42. PubMed ID: 22230124
[TBL] [Abstract][Full Text] [Related]
60. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase.
Weinreb N; Taylor J; Cox T; Yee J; vom Dahl S
Am J Hematol; 2008 Dec; 83(12):890-5. PubMed ID: 18819093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]